The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
p53, p21, pRB, and p16 Expression Predict Clinical Outcome in Cystectomy With Bladder Cancer
Abstract
Purpose: To determine whether p53, p21, pRB, and/or p16 expression is associated with bladder cancer stage, progression, and prognosis. Patients and Methods: Immunohistochemical staining for p53, p21, pRB, and p16 was carried out on serial sections from archival specimens of 80 patients who underwent bilateral pelvic lymphadenectomy and radical cystectomy for bladder cancer (median follow-up, 101 months). Results: p53, p21, and pRB or p16 expression was altered in 45 (56%), 39 (49%), and 43 (54%) tumors, respectively. Sixty-six patients (83%) had at least one marker altered, and 21 patients (26%) had all three altered. Abnormal expressions of p53, p21, and pRB/p16 expression were associated with muscle-invasive disease (P = .007, P = .003, and P = .003, respectively). The alteration of each marker was independently associated with disease progression (P ≤ .038) and disease-specific survival (P ≤ .039). In multivariable models that included standard pathologic features and p53 with p21 or p53 with pRB/p16, only p53 and lymph node metastases were associated with bladder cancer progression (P ≤ .026) and death (P ≤ .028). In models that included p21 and pRB/p16, only p21 and lymph node metastases were associated with bladder cancer progression (P ≤ .022) and death (P ≤ .028). In a model that included the combined variables p53/p21 and pRB/p16, only p53/p21 and lymph node status were associated with bladder cancer progression (P ≤ .047) and death (P ≤ .036). The incremental number of altered markers was independently associated with an increased risk of bladder cancer progression (P = .005) and mortality (P = .007). Conclusion: Although altered expression of each of the four cell cycle regulators is associated with bladder cancer outcome in patients undergoing radical cystectomy, p53 is the strongest predictor, followed by p21, suggesting a more pivotal role of the p53/p21 pathway in bladder cancer progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
Sherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379 · cited 1×
“In addition, p21 acts to prevent pRB phosphorylation by inhibiting activation of cyclinE/cdk2 complexes that are required for pRB phosphorylation [25].”
BackgroundThe p53 tumour suppressor gene
Levine, A. J., Momand, J., & Finlay, C. A. (1991) · Nature · doi:10.1038/351453a0 · Cited by 3,788
Mice Lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control
Deng, C., Zhang, P., Wade Harper, J., Elledge, S. J., & Leder, P. (1995) · Cell · doi:10.1016/0092-8674(95)90039-x · Cited by 2,113
Zhang, Y., Xiong, Y., & Yarbrough, W. G. (1998) · Cell · doi:10.1016/s0092-8674(00)81401-4 · Cited by 1,626
Pomerantz, J., Schreiber-Agus, N., Liégeois, N. J., Silverman, A., Alland, L., Chin, L., Potes, J., Chen, K., Orlow, I., Lee, H.-W., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81400-2 · Cited by 1,521 · cited 1×
“transactivational silencing [9,10].”
New functional activities for the p21 family of CDK inhibitors.
LaBaer, J., Garrett, M. D., Stevenson, L. F., Slingerland, J. M., Sandhu, C., Chou, H. S., Fattaey, A., & Harlow, E. (1997) · Genes & Development · doi:10.1101/gad.11.7.847 · Cited by 1,402
The p16INK4a/CDKN2A tumor suppressor and its relatives
Ruas, M., & Peters, G. (1998) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(98)00017-1 · Cited by 911
Accumulation of Nuclear p53 and Tumor Progression in Bladder Cancer
Esrig, D., Elmajian, D., Groshen, S., Freeman, J. A., Stein, J. P., Chen, S.-C., Nichols, P. W., Skinner, D. G., Jones, P. A., & Cote, R. J. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411103311903 · Cited by 783
Induction of WAF1/CIP1 by a p53-independent pathway.
Michieli, P., Chedid, M., Lin, D. P., Pierce, J. H., Mercer, W. E., & Givol, D. (1994) · PubMed · Cited by 768
Sarkis, A. S., Dalbagni, G. M., Cordon‐Cardo, C., Zhang, Z., Sheinfeld, J., Fair, W. R., Herr, H. W., & Reuter, V. E. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.1.53 · Cited by 517
Esrig, D., Spruck, C., Nichols, P. W., Chaiwun, B., Steven, K. E., Groshen, S. G., Chen, S. C., Skinner, D. G., Jones, P. A., & Côté, R. J. (1993) · PubMed Central · Cited by 452
Altered Expression of the Retinoblastoma Gene Product: Prognostic Indicator in Bladder Cancer
Cordon-Cardo, C., Wartinger, D., Petrylak, D., Dalbagni, G., Fair, W. R., Fuks, Z., & Reuter, V. E. (1992) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/84.16.1251 · Cited by 334
Effect of p21WAF1/CIP1 Expression on Tumor Progression in Bladder Cancer
Stein, J. P., Ginsberg, D. A., Grossfeld, G. D., Chatterjee, S. J., Esrig, D., Dickinson, M. G., Groshen, S., Taylor, C. R., Jones, P. A., Skinner, D. G., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.14.1072 · Cited by 299
Brugarolas, J., Moberg, K., Boyd, S. D., Taya, Y., Jacks, T., & Lees, J. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.3.1002 · Cited by 276
Logothetis, C. J., Xu, H.-J., Ro, J. Y., Hu, S.-X., Sahin, A., Ordonez, N., & Benedict, W. F. (1992) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/84.16.1256 · Cited by 244
Self-citationBenedict, W. F., Lerner, S. P., Zhou, J., Shen, X., Tokunaga, H., & Czerniak, B. A. (1999) · Oncogene · doi:10.1038/sj.onc.1202452 · Cited by 131
Self-citationShariat, S. F., Kim, J., Raptidis, G., Ayala, G. E., & Lerner, S. P. (2003) · Urology · doi:10.1016/s0090-4295(03)00236-x · Cited by 131
Self-citationTokunaga, H., Shariat, S. F., Green, A. E., Brown, R. M., Zhou, J.-H., Benedict, W. F., & Lerner, S. P. (2001) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(01)01586-3 · Cited by 26
Self-citation(1995) · PubMed
Cited by
Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity
Knowles, M. A., & Hurst, C. D. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3817 · Cited by 1,247
Urothelial tumorigenesis: a tale of divergent pathways
Wu, X.-R. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1697 · Cited by 692
Prognostic Factors and Predictive Models in Renal Cell Carcinoma: A Contemporary Review
Sun, M., Shariat, S. F., Cheng, C., Ficarra, V., Murai, M., Oudard, S., Pantuck, A. J., Zigeuner, R., & Karakiewicz, P. I. (2011) · European Urology · doi:10.1016/j.eururo.2011.06.041 · Cited by 325
Self-citationDinney, C. P. N., McConkey, D. J., Millikan, R. E., Wu, X., Bar-Eli, M., Adam, L., Kamat, A. M., Siefker-Radtke, A. O., Tuziak, T., Sabichi, A. L., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.08.002 · Cited by 290
Self-citationMitra, A. P., Datar, R. H., & Cote, R. J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.2073 · Cited by 284
Metadata
- Authors
- Shariat, S. F., Tokunaga, H., Zhou, J., Kim, J., Ayala, G. E., Benedict, W. F., & Lerner, S. P.
- Venue
- Journal of Clinical Oncology
- Published
- 2004-03-15
- Volume
- 22
- Issue
- 6
- Pages
- 1014-1024
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2157153728
- Cited by
- 327
- References
- 20
- FWCI
- 18.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.